Arcutis Biotherapeutics, Inc. (ARQT)
Health Care ยท Pharmaceutical Preparations
Arcutis Biotherapeutics, Inc. (ARQT) is listed on Nasdaq, where its shares have traded since January 31, 2020. SentiSense covers Arcutis Biotherapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Frank Watanabe is its chief executive officer. The company reports 354 employees, and its corporate website is www.arcutis.com.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 260 institutions reported holding ARQT, with 131.2 million shares worth $3.4 billion in aggregate. The largest reported holders were Suvretta Capital Management, BlackRock and Frazier Life Sciences Management. Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter.
More on ARQT
- ARQT sentiment: whether news and social coverage of Arcutis Biotherapeutics, Inc. leans bullish or bearish, and the stories driving it.
- ARQT ownership: all 260 reporting institutions, plus insider and congressional trades.
- ARQT financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Arcutis Biotherapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs.
What sector is ARQT in?
SentiSense classifies Arcutis Biotherapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ARQT stock trade?
Arcutis Biotherapeutics, Inc. (ARQT) is listed on Nasdaq, where its shares have traded since January 31, 2020.
Who is the CEO of Arcutis Biotherapeutics, Inc.?
Frank Watanabe is the chief executive officer of Arcutis Biotherapeutics, Inc..